Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism

被引:77
作者
Klipping, C
Marr, J [1 ]
机构
[1] Schering AG, D-13342 Berlin, Germany
[2] Dinox Med Invest, NL-6524 TX Nijmegen, Netherlands
关键词
oral contraceptives; drospirenone; lipid metabolism; carbohydrate metabolism;
D O I
10.1016/j.contraception.2004.12.005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the effect of ethinyl estradiol 20 mu g/drospirenone 3 mg (EE 20 mu g/DRSP 3 mg) administered according to a 24/4 regimen with ethinyl estradiol 20 mu g/desogestrel 150 mu g (EE 20 mu g/DSG 150 mu g) administered according to the conventional 21/7 regimen on lipid, carbohydrate and hemostatic parameters. Study Design: In this open-label study, healthy women were randomized to EE 20 mu g/DRSP 3 mg or EE 20 mu g/DSG 150 mu g for seven cycles. Mean differences in high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol levels at cycle 7 compared to baseline were assessed. Secondary variables included changes in other lipid, hemostatic and carbohydrate parameters. Results: Both treatments increased HDL-cholesterol, but decreased LDL-cholesterol by a comparable extent. Although slightly elevated in both groups, blood glucose and C-peptide levels measured during oral glucose tolerance tests were within normal reference ranges at cycle 7. Overall, the differences in lipid, hemostatic or carbohydrate parameters were not significant between the two treatments. Conclusion: EE 20 mu g/DRSP 3 mg has a good safety profile comparable with EE 20 mu g/DSG 150 mu g. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 29 条
[1]  
[Anonymous], 1993, JAMA, V269, P505
[2]   THE ANALYSIS OF VAGINAL BLEEDING PATTERNS INDUCED BY FERTILITY REGULATING METHODS [J].
BELSEY, EM ;
MACHIN, D ;
DARCANGUES, C .
CONTRACEPTION, 1986, 34 (03) :253-260
[3]   LIPID-METABOLISM EFFECTS WITH DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVES [J].
BURKMAN, RT .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (03) :1033-1040
[4]   Biological coagulation findings in third-generation oral contraceptives [J].
Conard, J .
HUMAN REPRODUCTION UPDATE, 1999, 5 (06) :672-680
[5]   A COMPARATIVE METABOLIC STUDY OF 2 LOW-ESTROGEN-DOSE ORAL-CONTRACEPTIVES CONTAINING DESOGESTREL OR GESTODENE PROGESTINS [J].
CROOK, D ;
GODSLAND, IF ;
WORTHINGTON, M ;
FELTON, CV ;
PROUDLER, AJ ;
STEVENSON, JC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 169 (05) :1183-1189
[6]   A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids, and carbohydrate metabolism [J].
Endrikat, J ;
Klipping, C ;
Gerlinger, C ;
Ruebig, A ;
Schmidt, W ;
Holler, T ;
Düsterberg, B .
CONTRACEPTION, 2001, 64 (04) :235-241
[7]   An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables [J].
Endrikat, J ;
Klipping, C ;
Cronin, M ;
Gerlinger, C ;
Ruebig, A ;
Schmidt, W ;
Düsterberg, B .
CONTRACEPTION, 2002, 65 (03) :215-221
[8]  
Foidart J M, 2000, Eur J Contracept Reprod Health Care, V5 Suppl 3, P25
[9]  
Foidart J M, 2000, Eur J Contracept Reprod Health Care, V5, P124, DOI 10.1080/13625180008500387
[10]   A 12-month clinical investigation with a 24-day regimen containing 15 μg ethinylestradiol plus 60 μg gestodene with respect to hemostasis and cycle control [J].
Fruzzetti, F ;
Genazzani, AR ;
Ricci, C ;
De Negri, F ;
Bersi, C ;
Carmassi, F .
CONTRACEPTION, 2001, 63 (06) :303-307